Cytiva has trusted Cell Boost in the production of five FDA-approved molecules.
Public source
Publisher name
Public post
Feed selection is about more than today's experiment. It's about building confidence in tomorrow's process. Cell Boost is trusted in the production of five FDA-approved…
Company
Cytiva
We envision a world in which access to life-changing therapies transforms human health.
- Industry
- Biotechnology Research
- Location
- Global, OO
- Company size
- 5,001–10,000 employees
About Cytiva
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. We are part of Danaher, a global science and technology leader. Along with other Danaher businesses, we accelerate the impact of tomorrow’s science and technology innovation to improve human health. Visit https://www.cytiva.com/privacy to review our privacy policy.
See moreLatest activity
Latest activity from Cytiva
51 signals
Products & Services
Cytiva introduced process-specific filter validation services designed to support low and ultra-low product volumes.
Presence & Recognition
Cytiva completed Day 3 of the Exmouth to Newquay challenge, covering 156.7 km and 2,350 m of climbing.
Products & Services
Cytiva introduced HyClone boost expression supplements designed to support transient transfection workflows and increase recombinant protein and rAAV production.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Sino Biological, Inc.
Sino Biological, Inc. used Cytiva’s Biacore SPR system to screen all 200 candidates in just 4.5 hours.
Research & Knowledge
INFORS HT
INFORS HT published an application note detailing how bioreactors, TFF loops, perfusion rates, nutrient dosing, pH, and dissolved oxygen were monitored and controlled within a single process environment for complex perfusion workflows.
Research & Knowledge
Fluidic Sciences
Fluidic Sciences notes that Merck KGaA used Cyto-Mine® to progress from cell preparation to confirmed recombinant antibodies in 4 weeks.
Research & Knowledge
Bio-Works Technologies
Bio-Works Technologies published a study showing that a WorkBeads™ 40S capture step reduced impurity load from 27.5% to 12% before the feed ever reached the reversed phase step, achieving 99.7% purity against a 99% target at 90% yield.
Research & Knowledge
Sino Biological Europe